Drugs / AZINTUXIZUMAB VEDOTIN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02951117 | Aug 2017 → Jul 2020 | plasma cell myeloma | AbbVie | Withdrawn | No outcome recorded |
| Phase 1 | NCT02462525 | May 2015 → Dec 2017 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZINTUXIZUMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297859 ↗ |
| Known as | ABBV-838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02951117 ↗ |
| Known as | Azintuxizumab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297859 ↗ |
| Known as | Azintuxizumab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297859 ↗ |
| Route | Intravenous | “Eligible patients (≥18 years) received ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W).” PMID 31969330 ↗ Jan 2020 |
| Target | SLAMF7 | “First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.” PMID 31969330 ↗ Jan 2020 |